Abstract:Pulmonary arterial hypertension (PAH) is a progressive, chronic, and incurable inflammatory pulmonary vascular disease characterized by significant sex bias and largely unexplored microbial-associated molecular mechanisms that may influence its development and sex prevalence across various subgroups. PAH can be subclassified as idiopathic, heritable, or associated with conditions such as connective tissue diseases, congenital heart defects, liver disease, infections, and chronic exposure to drugs or toxins. During PAH progression, lung vascular endothelial cells (ECs) undergo dramatic morphofunctional transformations in response to acute and chronic inflammation. These transformations include the appearance and expansion of abnormal vascular cell phenotypes such as those derived from apoptosis-resistant cell growth and endothelial-to-mesenchymal transition (EndoMT). Compelling evidence indicates that these endothelial phenotypes seem to be triggered by chronic lung vascular injury and dysfunction, often characterized by reduced secretion of vasoactive molecules like nitric oxide (NO) and exacerbated response to vasoconstrictors such as Endothelin-1 (ET-1), both long-term known contributors of PAH pathogenesis. This review sheds light on the mechanisms of EC dysfunction, apoptosis, and EndoMT in PAH, aiming to unravel the intricate interactions between ECs, pathogens, and other cell types that drive the onset and progression of this devastating disease. Ultimately, we hope to provide an overview of the complex functions of lung vascular ECs in PAH, inspiring novel therapeutic strategies that target these dysfunctional cells to improve the treatment landscape for PAH, particularly in the face of current and emerging global pathogenic threats.

Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension

Epigenetic Regulation of Pulmonary Arterial Hypertension

Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Epigenetic Modulation in the Initiation and Progression of Pulmonary Hypertension.

Regulatory role of autophagy in development of pulmonary artery hypertension

Unraveling the role of HIF and epigenetic regulation in pulmonary arterial hypertension: implications for clinical research and its therapeutic approach

Unraveling the epigenetic landscape of pulmonary arterial hypertension: implications for personalized medicine development

Endothelial cells in the pathogenesis of pulmonary arterial hypertension

Panorama of artery endothelial cell dysfunction in pulmonary arterial hypertension

Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension

Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?

Epigenetic regulation of programmed cell death in hypoxia-induced pulmonary arterial hypertension

Endothelial Cell Energy Metabolism, Proliferation, and Apoptosis in Pulmonary Hypertension

Emerging Epigenetic Targets and Their Molecular Impact on Vascular Remodeling in Pulmonary Hypertension

Abstract 159: Endothelial Fatty Acid-binding Proteins Contribute to the Pathogenesis of Pulmonary Hypertension

Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension

The role of chemokines and chemokine receptors in pulmonary arterial hypertension

Updated perspective of EPAS1 and the role in pulmonary hypertension

Exploring the pathogenesis of pulmonary vascular disease

Epigenetic Regulation of Angiogenesis in Peripheral Artery Disease